1. HBW Insight
  2. >>Wellness
  3. >>Policy & Regulation
  4. >>Regulation

FDA’s Proposed IND Study For ‘Abuse Potential’ Could Close US Kratom Supplement Market

 
• By Malcolm Spicer

RFP states FDA "previously warned consumers about the use of Kratom (Mitragyna speciosa)” and although botanical’s “use is prevalent, to date, clinical evaluations of abuse potential have not been performed.”

• Source: Alamy

The US Food and Drug Administration has asked for proposals to conduct an investigational new drug trial for kratom “to help characterize its abuse potential” after previously recommending scheduling ingredients from the botanical as controlled substances.

The agency’s request for proposals states the FDA “has previously warned consumers about the use of Kratom (Mitragyna speciosa), a plant endogenous to Southeast Asia” and although the botanical’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Kennedy’s Balancing Act: Push MAHA, Trim Regs

 
• By Malcolm Spicer

Same-day announcements of RFIs from HHS secretary cover nutrient review process for infant formula and Kennedy’s “10-to-1 deregulatory policy” as part of president’s “broader federal effort to reduce regulatory burdens and increase transparency.”

Supplementation Unlikely To Help With Hereditary Hair Loss, Says German Agency

 
• By David Ridley

Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”

NAD Asks FTC To Pull Bandage Off Firm’s Plan To Exhaust Inventory Using ‘2X Faster Healing’ Claim

 
• By Malcolm Spicer

After National Advertising Division attorneys, in a review prompted by a challenge by Band-Aid line marketer Kenvue, recommended ASO LLV cease use of its “up to 2x faster healing” claim, they determined the firm had not fully complied.